Selvigaltin (GB1211) is the first small-molecule, orally delivered galectin-3 inhibitor to be discovered. It is developed by Galecto Biotech, which is testing the molecule to see if it reduces decompensated cirrhosis and resistance to checkpoint inhibitors (a type of anti-cancer drug).
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.